Takara Bio Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis

Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.
TOKYO, Japan | Jan 11, 2007 |
Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.

Takara Bio's RetroNectin method was used under license in the clinical trial.

For the Retro Nectin treatment, VM106 utilizes a retro virus vector to inject gp91, the normal treatment gene, into the extracted haematopoietic stem cell of the patient. Afterwards a sample of this is injected back into the patient.

By Aki Tsukioka, JCN Staff Writer

SOURCE: JCN

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top